Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to RadioTherapy (ADOPT): Study Protocol for a Randomised Phase III Trial

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 May 3

PMID 35501744

Authors

J Janssen

F H E Staal

C L Brouwer

J A Langendijk

I J de Jong

R J A van Moorselaar

E Schuit

J F Verzijlbergen

R J Smeenk

S Aluwini

Affiliations

Soon will be listed here.

Abstract

Background: More than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical recurrence within 2 years. This recurrence rate emphasises the need for improved treatment and patient selection. In line with the treatment of primary PCa, the efficacy of MDRT may be enhanced when combined with androgen-deprivation therapy (ADT). Furthermore, the availability of PSMA PET/CT offers an excellent tool for optimal patient selection for MDRT. This phase III randomised controlled trial will investigate the role of the addition of ADT to MDRT in oligo-recurrent PCa patients selected with PSMA PET/CT to enhance oncological outcome.

Methods: Two hundred and eighty patients will be randomised in a 1:1 ratio to the standard treatment arm (MDRT alone) or the experimental arm (MDRT + 6 months ADT). Patients with biochemical recurrence after primary treatment of PCa presenting with ≤ 4 metastases will be included. The primary endpoint is the 2.5-year metastases progression-free survival (MPFS). Secondary endpoints are acute and late toxicity, quality of life, biochemical progression-free survival, overall survival, and the sensitivity of the PSMA PET/CT for detecting oligometastases at low PSA-levels. So far, between March 2020 and December 2021, one hundred patients have been included.

Discussion: This phase III randomised controlled trial will assess the possible benefit of the addition of 6 months ADT to MDRT on metastases progression-free survival, toxicity, QoL and survival in PCa patients with 1-4 recurrent oligometastatic lesions.

Trial Registration: ClinicalTrials.gov, NCT04302454 . Registered 10 March 2020.

Citing Articles

Pelvic lymph node motion during cone-beam computed tomography guided stereotactic radiotherapy.

Janssen J, Staal F, Langendijk J, Both S, Brouwer C, Aluwini S Clin Transl Radiat Oncol. 2024; 47:100794.

PMID: 38798748 PMC: 11127188. DOI: 10.1016/j.ctro.2024.100794.

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer.

von Eyben R, Hoffmann M, Soydal C, Virgolini I, Tuncel M, Gauthe M Biomedicines. 2023; 11(9).

PMID: 37760775 PMC: 10525266. DOI: 10.3390/biomedicines11092333.

Simple immobilization for stereotactic radiotherapy aimed at pelvic metastases.

Janssen J, Brouwer C, Staal F, van Herpt H, Both S, Langendijk J Phys Imaging Radiat Oncol. 2023; 27:100460.

PMID: 37435559 PMC: 10331836. DOI: 10.1016/j.phro.2023.100460.

A Review of Modern Imaging Landscape for Prostate Cancer: A Comprehensive Clinical Guide.

Gravestock P, Somani B, Tokas T, Rai B J Clin Med. 2023; 12(3).

PMID: 36769834 PMC: 9918161. DOI: 10.3390/jcm12031186.

A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis.

von Eyben R, Kapp D, Hoffmann M, Soydal C, Uprimny C, Virgolini I Cancers (Basel). 2022; 14(21).

PMID: 36358880 PMC: 9657957. DOI: 10.3390/cancers14215461.

References

Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes R . Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2014; 67(5):852-63. DOI: 10.1016/j.eururo.2014.09.004. View

Afshar-Oromieh A, Wolf M, Kratochwil C, Giesel F, Combs S, Dimitrakopoulou-Strauss A . Comparison of ⁶⁸Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro Oncol. 2014; 17(2):312-9. PMC: 4288516. DOI: 10.1093/neuonc/nou131. View

Ploussard G, Almeras C, Briganti A, Giannarini G, Hennequin C, Ost P . Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. J Urol. 2015; 194(4):983-8. DOI: 10.1016/j.juro.2015.04.103. View

Cox B, Spratt D, Lovelock M, Bilsky M, Lis E, Ryu S . International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012; 83(5):e597-605. DOI: 10.1016/j.ijrobp.2012.03.009. View

Phillips R, Shi W, Deek M, Radwan N, Lim S, Antonarakis E . Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020; 6(5):650-659. PMC: 7225913. DOI: 10.1001/jamaoncol.2020.0147. View

Sountoulides P, Rountos T . Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol. 2013; 2013:240108. PMC: 3747499. DOI: 10.1155/2013/240108. View

Palma D, Olson R, Harrow S, Gaede S, Louie A, Haasbeek C . Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393(10185):2051-2058. DOI: 10.1016/S0140-6736(18)32487-5. View

Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N . Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate. 2014; 74(3):297-305. DOI: 10.1002/pros.22750. View

Eiber M, Maurer T, Souvatzoglou M, Beer A, Ruffani A, Haller B . Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015; 56(5):668-74. DOI: 10.2967/jnumed.115.154153. View

10.

Abdollah F, Sammon J, Reznor G, Sood A, Schmid M, Klett D . Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. Eur J Surg Oncol. 2015; 41(11):1529-39. DOI: 10.1016/j.ejso.2015.06.011. View

11.

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

12.

Ost P, Jereczek-Fossa B, van As N, Zilli T, Muacevic A, Olivier K . Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. Eur Urol. 2015; 69(1):9-12. DOI: 10.1016/j.eururo.2015.07.004. View

13.

Cornford P, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2020; 79(2):263-282. DOI: 10.1016/j.eururo.2020.09.046. View

14.

Denham J, Steigler A, Lamb D, Joseph D, Turner S, Matthews J . Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011; 12(5):451-9. DOI: 10.1016/S1470-2045(11)70063-8. View

15.

Bolla M, van Tienhoven G, Warde P, Dubois J, Mirimanoff R, Storme G . External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010; 11(11):1066-73. DOI: 10.1016/S1470-2045(10)70223-0. View

16.

Kernan W, Viscoli C, Makuch R, Brass L, Horwitz R . Stratified randomization for clinical trials. J Clin Epidemiol. 1999; 52(1):19-26. DOI: 10.1016/s0895-4356(98)00138-3. View

17.

Singh D, Yi W, Brasacchio R, Muhs A, Smudzin T, Williams J . Is there a favorable subset of patients with prostate cancer who develop oligometastases?. Int J Radiat Oncol Biol Phys. 2003; 58(1):3-10. DOI: 10.1016/s0360-3016(03)01442-1. View

18.

Perera M, Papa N, Christidis D, Wetherell D, Hofman M, Murphy D . Sensitivity, Specificity, and Predictors of Positive Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016; 70(6):926-937. DOI: 10.1016/j.eururo.2016.06.021. View

19.

DAmico A, Chen M, Renshaw A, Loffredo M, Kantoff P . Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299(3):289-95. DOI: 10.1001/jama.299.3.289. View

20.

Nguyen P, Alibhai S, Basaria S, DAmico A, Kantoff P, Keating N . Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2014; 67(5):825-36. DOI: 10.1016/j.eururo.2014.07.010. View